<?xml version="1.0" encoding="UTF-8"?>
<p>Hepatitis A is preventable by vaccination. Currently, inactivated HAV vaccines are used as standard vaccination agents and are licensed for administration in a 2-dose schedule given at 6- to 12-month intervals (single dose plus booster dose). Since 1992, 4 interchangeable inactivated monovalent hepatitis A vaccines have become, available which provided protection against all strains of the virus [
 <xref rid="b24-ir-2019-09155" ref-type="bibr">24</xref>]. Protective levels of anti-HAV viruses, persists for at least 20â€“25 years after vaccination [
 <xref rid="b25-ir-2019-09155" ref-type="bibr">25</xref>]. Although a live, attenuated hepatitis A vaccine is used in some areas because it is cheaper, it has a major disadvantage in that reverse mutation of the live vaccine strains is theoretically possible [
 <xref rid="b26-ir-2019-09155" ref-type="bibr">26</xref>]. Moreover, live vaccines do not offer post-exposure protection because they only illicit a slow immune response [
 <xref rid="b26-ir-2019-09155" ref-type="bibr">26</xref>].
</p>
